Przejdź do zawartości
Merck

A patient-derived cellular model for Huntington's disease reveals phenotypes at clinically relevant CAG lengths.

Molecular biology of the cell (2018-09-27)
Claudia Lin-Kar Hung, Tamara Maiuri, Laura Erin Bowie, Ryan Gotesman, Susie Son, Mina Falcone, James Victor Giordano, Tammy Gillis, Virginia Mattis, Trevor Lau, Vickie Kwan, Vanessa Wheeler, Jonathan Schertzer, Karun Singh, Ray Truant
ABSTRAKT

The huntingtin protein participates in several cellular processes that are disrupted when the polyglutamine tract is expanded beyond a threshold of 37 CAG DNA repeats in Huntington's disease (HD). Cellular biology approaches to understand these functional disruptions in HD have primarily focused on cell lines with synthetically long CAG length alleles that clinically represent outliers in this disease and a more severe form of HD that lacks age onset. Patient-derived fibroblasts are limited to a finite number of passages before succumbing to cellular senescence. We used human telomerase reverse transcriptase (hTERT) to immortalize fibroblasts taken from individuals of varying age, sex, disease onset, and CAG repeat length, which we have termed TruHD cells. TruHD cells display classic HD phenotypes of altered morphology, size and growth rate, increased sensitivity to oxidative stress, aberrant adenosine diphosphate/adenosine triphosphate (ADP/ATP) ratios, and hypophosphorylated huntingtin protein. We additionally observed dysregulated reactive oxygen species (ROS)-dependent huntingtin localization to nuclear speckles in HD cells. We report the generation and characterization of a human, clinically relevant cellular model for investigating disease mechanisms in HD at the single-cell level, which, unlike transformed cell lines, maintains functions critical for huntingtin transcriptional regulation and genomic integrity.